Jadwiga Bienkowska

Senior Director, Head of Computational Biology Oncology R&D
Jadwiga Bienkowska
Dr. Bienkowska is a Sr. Director and Head of Computational Biology at Pfizer in Oncology Research and Development. The team led by Dr. Bienkowska is responsible for computational aspects of projects from early discovery through late stage clinical development in Oncology. Responsibilities include development and implementation of strategies for biomarkers/target identification and patient selection through cutting edge, integrative analysis of large-scale data from preclinical models, patient registries and clinical trials in collaboration with discovery and clinical teams. Dr. Bienkowska has deep expertise in developing and applying NGS-based technologies to target discovery and investigations of mechanisms of resistance in clinical trials in therapeutic areas spanning Oncology, Immunology and Neurology. Dr. Bienkowska actively collaborates with academic groups developing novel NGS and computational technologies. Her academic appointments include: Adjunct Professor in the Department of Medicine, Genetics at UCSD, Visiting Scientist at CSAIL, MIT and Adjunct Professor in Biomedical Engineering Department at Boston University. Dr. Bienkowska has PhD degree in Physics from the University of Chicago and completed postdoctoral training at Harvard and Dana Farber Cancer Institute in Biological Chemistry and Molecular Pharmacology.


No data was found

Live Webinar

Genomic Testing Strategies For Research Through To Clinical Studies: Profiling Of Genomics From NeoGenomics' Perspective

As genomic technologies develop and mature, adoption moves from the research environment into the clinical setting.  Previously, where Sanger and qPCR were the most rational choices to commercialize a diagnostic, NGS has become the biomarker testing methodology of choice.  Additionally, other emerging technologies and platforms like NanoString are finding their way into clinical trials as well as routine diagnostics.  With advances in technology, biomarker testing strategies have also evolved with a trend toward higher order multiplexed technologies as well as cross modality testing from a single sample to understand correlations between DNA, RNA and protein markers.  More data may be over burdensome to analyze, while a focused assay may miss an opportunity for collecting potentially valuable data.  Without a straightforward “rule of thumb” for which genomics technology to use when, thoughtful consultation is required.  This presentation will discuss the various factors and consideration points for choosing a genomic biomarker testing strategy to support biomarker projects.

Presented by James Yen, Senior Scientific Manager, CDx Programs, NeoGenomics

Thursday, 25 June 2020 | 15:30 BST